Table 2.
Evaluation of elicited antibodies against ARS-CoV-2 after the booster shots on day 21.
| Antibody’s feature | BBIBP-CorV | PastoCovac Plus | PastoCovac | P-value |
|---|---|---|---|---|
| Anti-spike IgG | ||||
| Titer rise GMT (95% CI) | 32.8 (20.2, 53.3) | 352.6 (261.5, 475.5) | 717.0 (485.4, 1059.3) | < 0.001a |
| Fourfold rise (n %) | 13 (24.3%) | 42 (63%) | 32 (50%) | < 0.001b |
| Fold rise GMT (95% CI) | 2.5 (1.9, 3.3) | 8.7 (6.1, 12.5) | 7.5 (4.8, 11.6) | < 0.001a |
| Neutralizing Ab | ||||
| Titer rise GMT (95% CI) | 0.9 (0.5, 1.5) | 3.7 (2.3, 6.0) | 2.9 (1.8, 4.6) | 0.004a |
| 4-old rise (n %) | 2 (3.2%) | 13 (19.7%) | 11 (17.5%) | 0.261b |
| Fold rise GMT (95% CI) | 1.3 (1.1, 1.5) | 2.8 (1.8, 4.2) | 2.0 (1.4, 2.7) | 0.054a |
| Anti-RBD | ||||
| Titer rise GMT (95% CI) | 31.0 (20.5, 46.7) | 916.3 (614.0, 1367.5) | 816.1 (599.3, 1111.4) | < 0.001a |
| Fourfold rise (n %) | 10 (16.1%) | 48 (72%) | 39 (61.9%) | < 0.001b |
| Fold rise GMT (95% CI) | 2.1 (1.6, 2.7) | 21.5 (12.5, 37.3) | 12.2 (7.5, 20.0) | < 0.001a |
GMT geometric mean titer, CI confidence interval.
aKruskal-Wallis test, bChi-square test.
Bold P values are indicated statistically significant.